Search

Your search keyword '"Force, Rex W"' showing total 164 results
Start Over Author "Force, Rex W"
164 results on '"Force, Rex W"'

2. Paradoxical reduction in HDL-C with fenofibrate and thiazolidinedione therapy in type 2 diabetes: The ACCORD Lipid Trial

Author

Linz, Peter E., Lovato, Laura C., Byington, Robert P., O'Connor, Patrick J., Leiter, Lawrence A., Weiss, Daniel, Force, Rex W., Crouse, John R., Ismail-Beigi, Faramarz, Simmons, Debra L., Papademetriou, Vasilios, Ginsberg, Henry N., and Elam, Marshall B.

Subjects
Fenofibrate -- Research -- Usage, Cholesterol, HDL -- Research -- Analysis -- Measurement, Type 2 diabetes -- Research -- Drug therapy -- Patient outcomes, Health
Abstract

OBJECTIVE To determine the occurrence of extremely low HDL cholesterol (HDL-C) among participants in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Lipid Trial and to examine the relationship [...]

Published
2014
Full Text
View/download PDF

44. Reliance on prothrombin time ratios causes significant errors in anticoagulation therapy

Author

Bussey, Henry I., Force, Rex W., Bianco, Theresa M., and Leonard, Anne D.

Subjects
Warfarin -- Dosage and administration, Prothrombin time -- Physiological aspects, Anticoagulants (Medicine) -- Health aspects, Health
Abstract

* Background.--The intensity of warfarin anticoagulation in the United States may be inappropriate if the international normalized ratio (INR) is not used, or if the international sensitivity index (ISI) of the thromboplastin is outside the range of 2.2 to 2.6. Methods.--Fifty-three hospital laboratories provided data on the sensitivity of their thromboplastin and whether they reported INR values. Additional data on thromboplastin sensitivity were obtained from 140 laboratories involved in the Stroke Prevention in Atrial Fibrillation study. The three major manufacturers of thromboplastin confirmed the range of thromboplastin sensitivity reported by the laboratories. Results.--Of 53 laboratories surveyed, 16 (30%) could not provide ISI data and only 11 (21%) reported INR results. Unlabeled thromboplastin was being used by 20% to 24% of laboratories, and only 8% to 20% were using thromboplastins with an ISI of 2.2 to 2.6. At the time the three manufacturers were contacted, they reported marketing thromboplastins with ISI values from 1.2 to 2.8, but none of the thromboplastins at that time had ISI values between 2.2 and 2.6. Conclusion.--Warfarin therapy in the United States is managed inappropriately because most laboratories do not report INRs and the variability in thromboplastin sensitivity produces misleading prothrombin time ratio results. Additionally, recent research may require reexamination if INR or ISI data were not provided. (Arch Intern Med. 1992;152:278-282)

Published
1992

46. Tapeworms, veggies, or pills?

Author

Force, Rex W. and Nahata, Milap C.

Subjects
Drugs -- Adverse and side effects, Vitamin B12 deficiency -- Case studies -- Complications and side effects, Histamine receptors -- Case studies, Health, Complications and side effects, Case studies
Abstract

CASE A 53-year-old white man presents with insidious and increasing arm weakness, bilateral shoulder pain, fatigue, and insomnia. He has a history of hypercholesterolemia, duodenal ulcer, osteoarthritis of the lower [...]

Published
1995

47. Pharmacy services in an ambulatory FFS setting can increase physician revenue

Author

Sadler, Melanie A. and Force, Rex W.

Subjects
Pharmaceutical services -- Management, Pharmaceuticals and cosmetics industries, Company business management, Management
Abstract

Idaho State University, Pocatello--Evidence in the literature has suggested that a pharmacist-run clinic provides quality care in chronic disease state management. In addition, previous studies have justified the value of [...]

Published
2002

Catalog

Books, media, physical & digital resources
See catalog results